O	0	10	Randomized
O	11	16	phase
O	17	20	III
O	21	26	trial
O	27	29	of
B-intervention	30	38	adjuvant
I-intervention	39	49	epirubicin
I-intervention	50	58	followed
I-intervention	59	61	by
I-intervention	62	78	cyclophosphamide
I-intervention	78	79	,
I-intervention	80	92	methotrexate
I-intervention	92	93	,
I-intervention	94	97	and
I-intervention	98	99	5
I-intervention	99	100	-
I-intervention	100	112	fluorouracil
I-intervention	113	114	(
I-intervention	114	117	CMF
I-intervention	117	118	)
O	119	125	versus
B-control	126	129	CMF
O	130	138	followed
O	139	141	by
O	142	152	epirubicin
O	153	155	in
O	156	164	patients
O	165	169	with
O	170	174	node
O	174	175	-
O	175	183	negative
O	184	186	or
O	187	188	1
O	188	189	-
O	189	190	3
O	191	195	node
O	195	196	-
O	196	204	positive
O	205	212	rapidly
O	213	226	proliferating
O	227	233	breast
O	234	240	cancer
O	240	241	.

O	242	250	Adjuvant
O	251	267	cyclophosphamide
O	267	268	,
O	269	281	methotrexate
O	281	282	,
O	283	286	and
O	287	288	5
O	288	289	-
O	289	301	fluorouracil
O	302	303	(
O	303	306	CMF
O	306	307	)
O	308	312	have
O	313	319	proven
O	320	326	highly
O	327	336	effective
O	337	339	in
O	340	347	rapidly
O	348	361	proliferating
O	362	368	breast
O	369	375	cancer
O	376	377	(
O	377	381	RPBC
O	381	382	)
O	382	383	.

O	384	386	It
O	387	390	has
O	391	395	also
O	396	400	been
O	401	405	seen
O	406	410	that
O	411	421	sequential
O	422	436	administration
O	437	439	of
O	440	451	doxorubicin
O	452	455	and
O	456	459	CMF
O	460	462	is
O	463	471	superior
O	472	474	to
O	475	480	their
O	481	492	alternation
O	492	493	,
O	494	504	especially
O	505	507	in
O	508	516	indolent
O	517	523	tumors
O	523	524	.

O	525	527	In
O	528	529	a
O	530	535	phase
O	536	539	III
O	540	545	study
O	545	546	,
O	547	549	we
O	550	559	evaluated
O	560	567	whether
O	568	576	adjuvant
O	577	587	epirubicin
O	588	589	(
O	589	590	E
O	590	591	)
O	592	600	followed
O	601	603	by
O	604	607	CMF
O	608	610	is
O	611	619	superior
O	620	622	to
O	623	626	the
O	627	634	inverse
O	635	643	sequence
O	644	646	in
O	647	651	RPBC
O	651	652	.

B-eligibility	653	661	Patients
I-eligibility	662	666	with
I-eligibility	667	671	node
I-eligibility	671	672	-
I-eligibility	672	680	negative
I-eligibility	681	683	or
I-eligibility	684	685	1
I-eligibility	685	686	-
I-eligibility	686	687	3
I-eligibility	688	692	node
I-eligibility	692	693	-
I-eligibility	693	701	positive
I-eligibility	702	706	RPBC
I-eligibility	707	708	(
I-eligibility	708	717	Thymidine
I-eligibility	718	726	Labeling
I-eligibility	727	732	Index
I-eligibility	733	734	>
I-eligibility	735	736	3
I-eligibility	736	737	%
I-eligibility	738	740	or
I-eligibility	741	753	histological
I-eligibility	754	759	grade
I-eligibility	760	761	3
I-eligibility	762	764	or
I-eligibility	765	766	S
I-eligibility	766	767	-
I-eligibility	767	772	phase
I-eligibility	773	774	>
I-eligibility	775	777	10
I-eligibility	777	778	%
I-eligibility	779	781	or
I-eligibility	782	786	Ki67
I-eligibility	787	788	>
I-eligibility	789	791	20
I-eligibility	791	792	%
I-eligibility	792	793	)
O	794	798	were
O	799	809	randomized
O	810	812	to
O	813	820	receive
O	821	822	E
O	823	824	(
O	824	827	100
O	828	830	mg
O	830	831	/
O	831	832	m
O	832	833	(
O	833	834	2
O	834	835	)
O	836	837	i
O	837	838	.
O	839	840	v
O	840	841	.
O	842	844	d1
O	844	845	,
O	846	849	q21
O	850	854	days
O	855	858	for
O	859	860	4
O	861	867	cycles
O	867	868	)
O	869	877	followed
O	878	880	by
O	881	884	CMF
O	885	886	(
O	886	889	600
O	889	890	,
O	891	893	40
O	893	894	,
O	895	898	600
O	899	901	mg
O	901	902	/
O	902	903	m
O	903	904	(
O	904	905	2
O	905	906	)
O	907	908	i
O	908	909	.
O	910	911	v
O	911	912	.
O	913	915	d1
O	916	919	and
O	920	921	8
O	921	922	,
O	923	926	q28
O	927	931	days
O	932	935	for
O	936	937	4
O	938	944	cycles
O	944	945	)
O	946	947	(
O	947	948	E
O	949	950	→
O	951	954	CMF
O	954	955	)
O	956	958	or
O	959	962	CMF
O	963	971	followed
O	972	974	by
O	975	976	E
O	977	978	(
O	978	981	CMF
O	982	983	→
O	984	985	E
O	985	986	)
O	987	989	or
O	990	993	CMF
O	994	997	for
O	998	999	6
O	1000	1006	cycles
O	1006	1007	.

O	1008	1012	From
O	1013	1021	November
O	1022	1026	1997
O	1027	1029	to
O	1030	1038	December
O	1039	1043	2004
O	1043	1044	,
B-total-participants	1045	1049	1066
O	1050	1058	patients
O	1059	1063	were
O	1064	1072	enrolled
O	1072	1073	:
O	1074	1075	E
O	1076	1077	→
O	1078	1081	CMF
B-intervention-participants	1082	1085	440
O	1085	1086	,
O	1087	1090	CMF
O	1091	1092	→
O	1093	1094	E
B-intervention-participants	1095	1098	438
O	1098	1099	,
O	1100	1103	and
O	1104	1107	CMF
B-control-participants	1108	1111	188
O	1111	1112	.

O	1113	1115	At
O	1116	1117	a
O	1118	1124	median
O	1125	1131	follow
O	1131	1132	-
O	1132	1134	up
O	1135	1137	of
O	1138	1140	69
O	1141	1147	months
O	1147	1148	,
B-outcome	1149	1150	5
I-outcome	1150	1151	-
I-outcome	1151	1155	year
I-outcome	1156	1158	OS
O	1159	1162	was
B-iv-bin-percent	1163	1165	91
I-iv-bin-percent	1165	1166	%
O	1167	1168	(
O	1168	1170	95
O	1170	1171	%
O	1172	1174	CI
O	1175	1177	88
O	1177	1178	-
O	1178	1180	94
O	1180	1181	)
O	1182	1185	for
O	1186	1187	E
O	1188	1189	→
O	1190	1193	CMF
O	1194	1197	and
B-iv-bin-percent	1198	1200	93
I-iv-bin-percent	1200	1201	%
O	1202	1203	(
O	1203	1205	95
O	1205	1206	%
O	1207	1209	CI
O	1210	1212	90
O	1212	1213	-
O	1213	1215	95
O	1215	1216	)
O	1217	1220	for
O	1221	1224	CMF
O	1225	1226	→
O	1227	1228	E
O	1228	1229	,
O	1230	1234	with
O	1235	1243	adjusted
O	1244	1250	hazard
O	1251	1256	ratio
O	1257	1259	of
O	1260	1261	0
O	1261	1262	.
O	1262	1264	88
O	1265	1266	(
O	1266	1268	95
O	1268	1269	%
O	1270	1272	CI
O	1273	1274	0
O	1274	1275	.
O	1275	1277	58
O	1277	1278	-
O	1278	1279	1
O	1279	1280	.
O	1280	1282	35
O	1282	1283	)
O	1283	1284	,
O	1285	1288	and
B-outcome	1289	1292	DFS
O	1293	1296	was
B-iv-bin-percent	1297	1299	80
I-iv-bin-percent	1299	1300	%
O	1301	1303	in
O	1304	1308	both
O	1309	1313	arms
O	1313	1314	,
O	1315	1319	with
O	1320	1328	adjusted
O	1329	1335	hazard
O	1336	1341	ratio
O	1342	1344	of
O	1345	1346	0
O	1346	1347	.
O	1347	1349	99
O	1350	1351	(
O	1351	1353	95
O	1353	1354	%
O	1355	1357	CI
O	1358	1359	0
O	1359	1360	.
O	1360	1362	73
O	1362	1363	-
O	1363	1364	1
O	1364	1365	.
O	1365	1367	33
O	1367	1368	,
O	1369	1372	Cox
O	1373	1378	model
O	1378	1379	)
O	1379	1380	.

B-outcome	1381	1388	Adverse
I-outcome	1389	1395	events
O	1396	1400	were
O	1401	1408	similar
O	1408	1409	,
O	1410	1415	apart
O	1416	1420	from
O	1421	1422	a
O	1423	1429	higher
O	1430	1434	rate
O	1435	1437	of
O	1438	1449	neutropenia
O	1450	1452	in
O	1453	1456	the
O	1457	1460	CMF
O	1461	1462	→
O	1463	1464	E
O	1465	1468	arm
O	1468	1469	.

O	1470	1472	No
O	1473	1482	important
O	1483	1494	differences
O	1495	1497	in
O	1498	1506	clinical
O	1507	1514	outcome
O	1515	1519	were
O	1520	1528	observed
O	1529	1536	between
O	1537	1540	the
O	1541	1544	two
O	1545	1554	different
O	1555	1564	sequences
O	1564	1565	,
O	1566	1572	making
O	1573	1577	both
O	1578	1579	a
O	1580	1585	valid
O	1586	1592	option
O	1593	1595	in
O	1596	1601	early
O	1602	1608	breast
O	1609	1615	cancer
O	1615	1616	.

O	1617	1624	Further
O	1625	1634	molecular
O	1635	1651	characterization
O	1652	1654	of
O	1655	1658	the
O	1659	1665	tumors
O	1666	1671	might
O	1672	1676	help
O	1677	1679	to
O	1680	1688	identify
O	1689	1698	subgroups
O	1699	1708	achieving
O	1709	1715	higher
O	1716	1723	benefit
O	1724	1728	from
O	1729	1735	either
O	1736	1744	sequence
O	1744	1745	.
